Objective: The severity of obesity is often more determined by the distribution of fat depots rather than by body weight itself. Therefore, the effect of rimonabant on fat distribution pattern was investigated in female candy-fed Wistar rats. Design: Female Wistar rats were fed a high fat, high carbohydrate (candy-) diet for 12 weeks. During the last 6 weeks rats were treated with rimonabant. Food intake and body weight development were investigated, as well as effects on total body fat, especially visceral fat and ectopic lipid accumulation in skeletal muscle and liver, determined by in vivo magnetic resonance imaging/magnetic resonance spectroscopy. Results: Candy-diet increased body weight, which was predominantly due to the increased total fat mass with predominance of visceral fat accumulation. Treatment with rimonabant fully reversed the weight gain and fat deposition in the visceral cavity and skeletal muscle, in contrast to pair feeding. In spite of an only transient reduction of food intake, body weight reduction, as well as normalized body fat, reduced visceral fat and intramyocellular lipids were maintained over the treatment period. Conclusions: We conclude that additional factors other than reduced caloric intake must be responsible for the improvements in these lipid parameters. The complete cluster of results is consistent with increased lipid oxidation caused by rimonabant.
Introduction
Obesity has become an epidemic not only in the industrialized, but also in the developing countries. [1] [2] [3] Comorbidities such as, for example, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein cholesterol and type 2 diabetes increase the risk of nonfatal and fatal cardiovascular events. 4 Human obesity is defined by the body mass index of above 30, 5 and pharmacotherapy is recommended not only for obese, but also for overweight individuals (body mass index above 27) when comorbidities are present. However, it has become more and more evident that not only total body fat mass determines the probability to develop comorbidities with increased risk for cardiovascular events, but the distribution of fat within the individual appear to be an important factor. It would appear that an accumulation of fat intra-abdominally (visceral adiposity) determines the major fat-associated risk factor. 6, 7 Therefore, waist circumference has become a simple and easily measurable parameter in humans and is an important part of the guidelines for identifying patients at a higher risk for developing cardiovascular diseases. 8 Already modest weight loss (5% of initial body weight loss) can result in significant health benefits, 9 predominantly if visceral adiposity is reduced.
The endocannabinoid system represents a promising new therapeutic target, which has an important role in the regulation of body weight, as well as in lipid or glucose metabolism. 10 Rimonabant, SR141716 is the first selective CB1 receptor antagonist. 11 It is an effective adjunct to diet and exercise in overweight or obese patients with associated risk factors, such as type 2 diabetes and dyslipidemia. In four placebo-controlled, multinational, double-blind, clinical RIO (Rimonabant In Obesity) studies, rimonabant has been shown not only to reduce body weight, but additionally to improve cardiometabolic risk factors, such as waist circumference, HbA1c, high-density lipoprotein and triglyceride in overweight/obese patients. [12] [13] [14] [15] The antiobese effect of rimonabant is ascribed to its CB1 receptor antagonism in the hypothalamus 16, 17 and nucleus accumbens, [18] [19] [20] resulting in reduced food intake predominantly of palatable food. In addition to the central effects on food intake and body weight, the improvement in the cardiometabolic risk factors, which have been shown to be beyond that what would be expected by body weight reduction alone, is hypothesized to involve also peripheral CB1 receptor antagonism. [12] [13] [14] [15] There are convincing results reported on the sustained body weight reduction in spite of the transient effects on food reduction in diet-induced obese mice, as well as in genetic rat models of obesity, such as the fa/fa Zucker rat. [21] [22] [23] [24] [25] The transience of reduced food intake in the presence of persistent reduction of body weight caused by rimonabant in rodent models has recently been elucidated to be caused by increased energy expenditure based on increased fat oxidation measured by indirect calorimetry, which contributed more to the sustained body weight reducing effect of rimonabant than reduced food intake. 26 In the diet-induced obese mice rimonabant caused a reduction of total body weight, which predominantly was the result of reduced subcutaneous fat depots. In contrast in the genetically obese rat studies rimonabant caused more a reduced 'body weight development' compared with untreated control rats, than really an absolute decrease in body weight. 24, 25 But similar to the studies with mice, the main effect of lower body weight was predominantly manifested in reduced total fat mass, which corresponds essentially to subcutaneous fat mass in genetic obese rat strains. Here, we describe the effect of rimonabant in the candydiet fed rat model using an integrated approach of noninvasive in vivo magnetic resonance spectroscopy/magnetic resonance imaging (MRS/MRI) measurements as well as biochemical analysis of muscle lipid contents (short-and long-chain acyl-CoAs (LCACoAs) in skeletal muscle of different fiber-type composition). The high fat, high carbohydrate candy-diet caused a moderate increase in total body weight, but this increase was predominantly related to elevated visceral fat mass. The accumulation of visceral fat represents more closely the phenotype of human obesity and metabolic syndrome compared with the excessive subcutaneous fat depots in genetic obese rat models. In this model, rimonabant decreased elevated body weight and this decrease was nearly exclusively related to a reduction of visceral fat mass.
Materials and methods

Animals
All experimental procedures were conducted in accordance to the German Animal Protection Law, as well as according to the international animal welfare legislation and rules. A total of 64 female Wistar rats (ca. 250 g, HsdCpb:WU, Harlan Winkelmann GmbH, Borchen, Germany) were used in this study. They were housed two per cage in an environmentally controlled room with a 1200-1200 hours light-dark circle (light on at 0600 hours) and ad libitum access to food and water. Standard rat chow (17.7 kJ g À1 , R/M-H, V1535, Ssniff, Soest, Germany) and a self-made candy-diet were used during the study.
Candy-diet
The candy-diet contained several candy bars in a ratio of 1:1:1:1 (Mars, Snickers, Twix, Bounty, Masterfoods, Viersen, Germany). The candy bars were frozen in dry ice, pulverized with a commercially available cutter (Kutter HTC, Alexanderwerk AG, Remscheid, Germany) and pressed into pellets. The ingredients of the candy-diet in comparison with the standard rat chow are summarized in Table 1 (analysis was performed by Landes-Untersuchungsanstalt für Futtermittel (LUFA), Kiel, Germany). The high fat (24%) and high carbohydrate (42%) candy-diet (21.3 kJ g
À1
) was used to induce a phenotype similar to human obesity with increased visceral fat deposits and metabolic syndrome.
Experimental design
The animals were separated into four weight-matched groups, each with n ¼ 16 animals. Group 1 served as a control group and was fed ad libitum with standard rat chow (control chow group) throughout the experiment of 12 weeks. The animals of the three other groups (group 2-4) also had access to standard rat chow, but additionally to the candy-diet (ad libitum for all three groups during the whole study period, except for the pair-fed group during the last 6 weeks). After the initial period of 6 weeks of candy-diet, the treatment period started. Group 2 served as the control group (control candy-diet group) and was fed with standard rat chow and candy-diet ad libitum. Rats of group 3 were treated orally with 10 mg kg À1 rimonabant (rimonabant candy-diet group). Rimonabant was synthesized by the chemical department of Sanofi-Aventis. It was administered by gavage once daily to rats in the postprandial state, which had free access to food (standard rat chow and candy-diet) and water during the previous night (dark-phase), at the . At 1700 hours each day, rats of group 4 were fed delayed with the amount of standard rat chow and candy-diet, the rimonabant-treated rats consumed the previous day (pair-fed candy-diet group). They had free access to water. All control rats received the vehicle only.
Subgroups (n ¼ 8) were used for noninvasive investigations on body fat distributions by in vivo MRS/MRI. The levels of intramyocellular lipids (IMCL), hepatocellular lipids (HepCl) and the total amount of body fat were determined by in vivo MRS at three different time points. They were measured at the beginning of the experiment (week 0), at the end of the initial period, before treatment started (week 6) and at the end of the treatment period (week 12). Visceral fat mass was determined by in vivo MRI, only at the end of the treatment period. After all, rats were fasted for 4 h. Blood samples were collected from the tip of the tail for determination of blood glucose, as well as retroorbitally for the determination of serum parameters (triglycerides, cholesterol, free fatty acids (FFA), insulin and leptin) in terminal isoflurane anesthesia. All blood samples were placed in serum gel tubes and were centrifuged at 4 1C at 5000 r.p.m. At the end of the study tissue samples (musculus soleus (SOL), musculus tibialis anterior (TIB) and musculus extensor digitorum longus (EDL)) were collected, immediately freeze-clamped in liquid nitrogen and stored in À80 1C for subsequent analysis of malonyl-CoA and LCACoAs.
Body weight and food consumption Body weight and food intake (standard rat chow and candydiet) of all animals were monitored twice weekly in the initial period (first 6 weeks of the study) and daily in the treatment period (last 6 weeks of the study). Food intake was measured per cage with n ¼ 2 animals separately for standard rat chow and candy-diet. On the basis of the caloric content of the standard rat chow and candy-diet, caloric intake was calculated and expressed as daily consumption in kJ per animal from n ¼ 8 cages per group (total number of animals n ¼ 16 per group).
In vivo MRS and MRI For all MRI and MRS determinations rats were anesthetized with isoflurane in N 2 O/O 2 and placed in suitable heated nonmagnetic devices. Temperature within the resonator was maintained at 22 1C.
Total amount of body fat. Magnetic resonance spectroscopy determination of body composition was carried out on a 4.7 Tesla Bruker Biospec spectrometer equipped with a whole body resonator (diameter: 197 mm, Bruker BioSpin MRI GmbH Ettlingen, Germany). Nonlocalized spectra were obtained using a one-pulse sequence with a relaxation delay of 3 s (16 averages, 5000 Hz sweep width, 1024 points).
Post-processing of the data consisted of zero filling, line broadening, Fourier transformation, phase and baseline correction. For spectral analysis, the water peak was referenced to 4.7 p.p.m. and two fixed integration regions were set: (a) from 8 to À1.5 p.p.m. for the total integral of water and fat signals and (b) from the relative minimum between the water and the lipid peak at B2 to À1.5 p.p.m. for the lipid peak. From the relative fat integral total body fat was calculated using the fat-water-ratio of 1.39 found in rats. 27 Detection of IMCL and HepCL. These two parameters were measured using a volume selective spectroscopic method (VSEL, Bruker); IMCL at 7 Tesla and HepCl at 4.7 Tesla as described previously. 28 IMCL was detected in the TIB using a slotted resonator for rf-excitation and an actively decoupled surface coil for signal detection (voxel size 1.6 Â 1.6 Â 3.2 mm 3 ) and expressed as IMCL-to-tCr ratio. HepCl was detected in a homogeneous region of the liver (4 mm 3 ) using a resonator for rf transmit and receive and expressed as fatto-water ratio. . Over 30 min, acetonitrile increased to 50%, whereas KH 2 PO 4 decreased to 20% and methanol remained constant at 30%. The sum of the major species (C16:0, C16:1, C18:0, C18:1, C18:2 and C20:4) was referred to as total LCACoAs, the sum of C16:0 and C18:0 was referred to as saturated (SFA), C16:1 and C18:1 was referred to as monounsaturated (MUFA) and the sum of C18:2 and C20:4 was referred to as polyunsaturated (PUFA) LCACoAs.
Statistical analysis
Data are presented as means ± s.e.m. Depending on the homogeneity of variances (Levène test), significant differences were tested by a one-way analysis of variance followed by a post hoc Newman Keuls multiple comparison test or by a Kruskal-Wallis analysis. When testing for differences between different time points, a two-way analysis of variance (for repeated measures) followed by a post hoc Newman Keuls multiple comparison test was used. For all statistical calculations the software package Everstat V5 (Sanofi-Synthelabo based on SAS 8) was used. A Po0.05 was considered to be statistically significant.
Results
The availability of the candy-diet in addition to the standard rat chow ad libitum resulted in an increase of body weight gain in female Wistar rats. Weight reached a plateau after 4 weeks on candy-diet that was about 10% above that of the group receiving standard rat chow solely (Figure 1a) . The rats obviously preferred the candy-diet, as the consumption of standard rat chow dropped to about 30% compared with the group receiving standard rat chow solely (data not shown). Owing to the different caloric densities of standard rat chow and candy-diet the rats of both control groups ate on energy constancy (Figure 1c) . Administration of rimonabant to rats that had free access to candy-diet and standard rat chow caused a decrease of body weight during the first week of treatment. The level of reduced body weight nearly reached the level of the control chow group and was maintained during the whole treatment period (Figure 1a) . Concomitantly, rimonabant caused a transient reduction of energy intake ( Figure 1c) . The change of body weight during the treatment period is shown in Figure 1b Visceral adiposity and rimonabant AW Herling et al receiving the candy-diet, including the pair-fed candy-diet group. There was a pronounced and sustained reduction of body weight; however, pair-fed rats differed in the second part of the treatment period and significantly gained more weight than the rimonabant-treated rats.
The MRS measurement of body fat (Figure 2a ) revealed that candy-diet fed rats had an increased deposition of fat within body tissues after 6 weeks of candy-diet, compared with rats fed with standard rat chow solely. Treating candydiet fed rats with rimonabant led to a strong decrease of their total body fat, even to control levels. In contrast, pair feeding did not lead to a comparable decrease. Similar results can be seen at the cellular level for the content of lipids in the muscle cell (IMCL, Figure 2b) . In hepatic cells (Figure 2c ), lipids were increased in candy-diet fed rats after the initial period, but here rimonabant did not lead to a reduction, whereas pair feeding did produce a decrease in lipid levels.
The evaluation of the visceral fat displayed that the candydiet led to an increase of visceral fat, which is shown by the images from three different animals per group (Figure 3c ). After 12 weeks of diet, the amount of visceral fat in candydiet fed rats increased about 50% (Figure 3a) . This accumulation of visceral fat can be seen in the all MRI slices, reaching from the caudal edge of the liver to the cranial edge of the iliac crest (Figure 3b ). Treatment with rimonabant significantly reduced the increased visceral fat mass in all evaluated slices to approximately to the level of the control chow group. A mere food reduction through pair feeding did not result in a comparable reduction of visceral fat.
The metabolic plasma parameters were measured after 12 weeks of candy-diet, at the end of the study. The high fat, high carbohydrate candy-diet led to a significant rise of triglyceride, cholesterol, FFA, leptin and blood glucose levels compared with standard rat chow fed rats (Figures 4a-e) . Insulin levels were increased as well, but failed to be significant (Figure 4f ). Administration of rimonabant to candy-diet fed rats resulted in significantly decreased serum triglyceride, FFA and leptin levels, according to the significant decrease in their total body fat. Insulin levels were reduced with rimonabant treatment, but failed to be significant. Cholesterol and blood glucose levels were unaffected by rimonabant compared with untreated candydiet fed rats. Pair feeding led to similar results regarding serum triglyceride and leptin levels, whereas FFA levels were not significantly decreased. In contrast to rimonabant treatment, blood glucose levels were significantly decreased by pair feeding. Cholesterol and insulin levels were unchanged by pair feeding compared with the control candy-diet fed rats.
Finally, analysis of the malonyl-CoA and LCACoA content (Figures 5a-f ) in different muscle types showed that the 12 weeks of candy-diet led to clear alterations. Malonyl-CoA was significantly decreased in SOL (Figure 5a ), but not in EDL (Figure 5b ) and TIB (Figure 5c ). Concurrently, there was a significant change in the LCACoA pattern in the different muscle types (Figures 5d-f) induced by the long-term candydiet. Saturated (SFA) and MUFA were strongly increased, according to their high content in the candy-diet, whereas PUFA were significantly decreased, although on absolute terms there was a comparable amount of PUFA in standard rat chow and candy-diet available (Table 1 ). Rimonabant Visceral adiposity and rimonabant AW Herling et al treatment did not result in reduced malonyl-CoA content in any muscle type compared with control candy-diet rats, although there was a tendency to reduced values in SOL and EDL. The pattern of LCACoAs was, compared with control candy-diet rats, unmodified by rimonabant. Mere pair feeding did not decrease malonyl-CoA content, nor significantly changed LCACoA pattern in the different muscle types, compared with control candy-diet rats.
Discussion
Female Wistar rats were chosen for this study, as they reached a plateau in their physiological body weight development in contrast to male rats, which progressively gained weight. 24, 25 In female rats, the candy-diet caused a body weight plateau, which was about 10% above that of the control rats receiving standard rat chow solely. 32 Therefore, this candy-diet animal model represented a model of just mild obesity compared with the genetic ones of, for example, fa/fa Zucker rats. 21, 24, 25 The control candy-diet rats had significantly elevated fat stores after 6 weeks on diet, which was maintained until the end of the study. Similarly, ectopic lipid accumulation in skeletal muscle and liver were sustained elevated in the control candy-diet fed rats. Predominantly, elevated IMCL is considered to represent a biomarker for muscle insulin resistance. 33, 34 As the proton signal of total body fat measured by in vivo MRS was transformed into grams of total body fat, 27 the increase in body weight could be ascribed predominantly to the increase in total body fat mass (Figure 2a) . Furthermore, the measurement of visceral fat, by in vivo MRI demonstrated a significant increase of this fat depot at the end of the study ( Figure 3) . As it has become more and more evident in humans that accumulation of fat intra-abdominally (visceral Visceral adiposity and rimonabant AW Herling et al adiposity) determines the major fat-associated risk factor, 6, 7 results form this candy-diet rat model might be more appropriate to resemble human pathophysiology than genetic rodent models with their excessive fat accumulation intra-abdominally but also subcutaneously. Visceral adiposity, even under conditions of basal lipolysis, determines increased delivery of fatty acids directly to the liver due to its anatomical location in connection with the blood drainage through the portal vein into the liver. In contrast, after intestinal fat digestion, fatty acids are absorbed and transported through the lymph duct into the aorta thereby bypassing the liver. This demonstrates that under conditions of normal physiology the delivery of fatty acids to the liver is marginal and that increased delivery due to visceral adiposity is combined with pathophysiological consequences with subsequent alterations of intermediary metabolism (for example, increased very low-density lipoprotein secretion, fatty acid-induced increased hepatic glucose production, hepatic insulin resistance). 7, 35 Rimonabant treatment for the last 6 weeks of the study caused an immediate, but transient decrease of energy intake. In spite of this transient effect, there was a sustained reduction of body weight reaching levels similar to that of the control chow group. Similarly, total body fat, IMCL and visceral fat were significantly reduced attaining the levels of the control chow group fed only with standard rat chow. In contrast, the pair-fed group differed significantly from the rimonabant candy-diet group at the end of the study, with respect to body weight gain, total body fat, IMCL and visceral fat. This demonstrated that reduced caloric intake was not only responsible for the pronounced improvements in biomarkers of fat metabolism. It has recently been reported that increased energy expenditure based on increased fat oxidation contributed more to the sustained body weight reducing effect of rimonabant than reduced food intake. Visceral adiposity and rimonabant AW Herling et al gram of liver (1.5% liver fat) for the candy-diet control as well as for the rimonabant-treated group; this indicates that these values are far below a fatty liver (45% liver fat). In this study, no reduction of the HepCL (Figure 2c ) was observed at the end of the study in the rimonabant candy-diet group. At a first view, this finding could be ascribed to an inhibited very low-density lipoprotein secretion from the liver, as serum triglycerides were additionally reduced. On the other hand, the nonreduced HepCL level for the rimonabant candy-diet group might be related to the pronounced reduction of visceral fat. The reduction of this fat depot drained the fatty acids, released by increased lipolysis, through the portal vein directly into the liver. It can be speculated that after 6 weeks of treatment, steady state reduction of visceral fat was not completely achieved and therefore increased lipolysis from visceral fat drained to the liver was still responsible for increased HepCL, and that a prolongation of the rimonabant treatment would finally result in a decrease of HepCL, too, similar to the decreased IMCL levels, which demonstrated much faster dynamics. 30, 31 Elevated lipid accumulation in the liver is combined with fatty acid-induced gluconeogenesis and thereby with increased hepatic glucose production. 7, 35 As during starvation, the liver is predominantly responsible for the maintenance of the blood glucose levels, and HepCL did not differ between candy-diet fed controls and rimonabant-treated , d ), musculus extensor digitorum longus (EDL; b, e), and musculus tibialis (TIB; c, f) in the control chow group, control candy-diet group, rimonabant candy-diet group, as well as in the pair-fed group at the end of the treatment period. LCACoAs were grouped in saturated fatty acids (SFA; C16:0 þ C18:0), monounsaturated fatty acids (MUFA; C16:1 þ C18:1), and polyunsaturated fatty acids (PUFA; C18:2 þ C20:4). Values are mean ± s.e.m., n ¼ 7-8. *Po0.05 vs control chow.
Visceral adiposity and rimonabant AW Herling et al rats, blood glucose levels were similar for both rat groups at the end of the study. Different blood glucose levels of the groups could be ascribed to the different HepCL levels. Levels of FFA were reduced for the rimonabant-treated group, which was consistent with reduced total fat mass. Surprisingly, in spite of elevated HepCL levels, serum triglycerides were also significantly reduced for rimonabant and comparable to that of the control chow group at the end of the study. This indicates that rimonabant, in the presence of similar food intake and concomitantly reduced total fat stores (subcutaneous and visceral), must cause increased combustion of fatty acids. This has already been postulated indirectly by gene expression studies in mice 36 as well as recently demonstrated by indirect calorimetric studies in rats. 26 As IMCL, a biomarker for muscle insulin resistance, was reduced, it seems likely that skeletal muscle represents the site of fatty acid oxidation. Malonyl-CoA represents the endogenous inhibitor of carnitin-palmitoyl-CoA transferase-1, the key enzyme of mitochondrial fatty acid oxidation. 37 However, rimonabant treatment did not significantly reduce malonyl-CoA content in any muscle compared with the respective control group. However, in this context it is important to consider that the measured concentrations of malonyl-CoA in the whole muscle are far above those which are necessary to block fatty acid oxidation in isolated mitochondria (34 nM according to McGarry et al.
38
). To solve this conflict, McGarry and Brown suggested 39 the possible distribution of total muscle malonyl-CoA to subcellular compartments unavailable to the carnitinpalmitoyl-CoA transferase-1 enzyme. Therefore, one could speculate that the majority of the malonyl-CoA content measured in whole muscle is not involved in the regulation of fatty acid oxidation and that, therefore, even small changes of the measured malonyl-CoA content in whole muscle might have relevant effects on lipid oxidation. Therefore, the numerically lower values of malonyl-CoA in the oxidative SOL and mixed EDL, but not in the glycolytic TIB, might be indicative for an increased lipid oxidation in muscle. This speculation is supported by recently published data that energy expenditure based on whole body fat oxidation measured by indirect calorimetry was increased during treatment with rimonabant in this animal model. 26 The differences observed in the patterns of LCACoAs, grouped as SFA, MUFA and PUFA, reflected only in part the ingredients of fatty acid species of the different diets. SFA and MUFA were elevated, similarly to their content in the candy-diet. Whereas PUFA were reduced in candy-diet fed rats compared with control chow rats, even though candydiet in absolute terms contained PUFA in the same amount as standard rat chow. In general, this argues for a preferred combustion of polyunsaturated fatty acids. The patterns of LCACoAs in the three investigated muscles were not obviously altered by rimonabant treatment or pair feeding. In this context, one has to consider that the measured levels represented the steady state levels, and that the fatty acid fluxes through the pool of LCACoAs might be different.
We conclude that rimonabant treatment caused a pronounced improvement of biomarkers of fat metabolism, particularly serum triglycerides and FFAs, as well as visceral adiposity. The reduction in body weight, total body fat and visceral fat, which was less pronounced in pair-fed rats, in the presence of similar energy intake to the respective control group at the end of the study, indicates that additional factors than reduced caloric intake must be responsible for the improvement of lipid parameters. Increased lipolysis and increased lipid oxidation as inherent pharmacological effects of rimonabant 26 might explain most of the findings in this study.
